| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30050862 | HIV | ENSG00000168906.13 | protein_coding | MAT2A | No | No | 4144 | P31153 |
| TVIS44000348 | HTLV-1 | ENSG00000168906.13 | protein_coding | MAT2A | No | No | 4144 | P31153 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MAT2A |
|---|---|
| DrugBank ID | DB00118 |
| Drug Name | Ademetionine |
| Target ID | BE0000304 |
| UniProt ID | P31153 |
| Regulation Type | cofactor |
| PubMed IDs | 11596649; 12023972; 12660248; 12671891 |
| Citations | Mudd SH, Cerone R, Schiaffino MC, Fantasia AR, Minniti G, Caruso U, Lorini R, Watkins D, Matiaszuk N, Rosenblatt DS, Schwahn B, Rozen R, LeGros L, Kotb M, Capdevila A, Luka Z, Finkelstein JD, Tangerman A, Stabler SP, Allen RH, Wagner C: Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. J Inherit Metab Dis. 2001 Aug;24(4):448-64.@@Farrar C, Clarke S: Altered levels of S-adenosylmethionine and S-adenosylhomocysteine in the brains of L-isoaspartyl (D-Aspartyl) O-methyltransferase-deficient mice. J Biol Chem. 2002 Aug 2;277(31):27856-63. Epub 2002 May 22.@@Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, Avila MA: L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003 May 30;278(22):19885-90. Epub 2003 Mar 26.@@Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Martin-Duce A, Fortes P, Caballeria J, Avila MA, Mato JM: Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology. 2003 Apr;124(4):940-8. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | 5'-deoxy-5'-thionucleosides |
| SMILES | C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N |
| Pathways | Phosphatidylcholine Biosynthesis PC(14:0/20:0); Phosphatidylcholine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z)); Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Phosphatidylcholine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z)); Phosphatidylcholine Biosynthesis PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); Phosphatidylcholine Biosynthesis PC(14:0/20:2(11Z,14Z)); Tyrosine Metabolism; Disulfiram Action Pathway; Hyperprolinemia Type II; Methylhistidine Metabolism; Phosphatidylcholine Biosynthesis PC(14:0/15:0); Mercaptopurine Action Pathway; L-Arginine:Glycine Amidinotransferase Deficiency; Tyrosinemia Type I; Betaine Metabolism; Catecholamine Biosynthesis; Phenytoin (Antiarrhythmic) Action Pathway; Glycine and Serine Metabolism; Carnitine Synthesis; Phosphatidylcholine Biosynthesis PC(14:0/20:1(11Z)); Phosphatidylcholine Biosynthesis PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z)); Hyperprolinemia Type I; Phosphatidylcholine Biosynthesis PC(14:0/18:2(9Z,12Z)); Phosphatidylcholine Biosynthesis PC(14:0/14:0); Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Phosphatidylcholine Biosynthesis PC(14:0/16:1(9Z)); Arginine and Proline Metabolism; Sarcosine Oncometabolite Pathway |
| PharmGKB | PA164754994 |
| ChEMBL | CHEMBL1088977 |
